Market Report Source

Overview

Psychiatric and neurological disorders constitute as much as 35% of
the disease burden in the seven major pharmaceutical markets,
representing continuing opportunities for pharma companies in the CNS
market. However, the increasing presence of generic products coupled
with low levels of innovative launches has resulted in a slowdown in
market growth and considerable unmet need across the spectrum of CNS
disorders.

The CNS Market Outlook to 2011 provides comprehensive
epidemiological analysis of the major CNS indications and key factors
impacting market and competitive dynamics. This report will enable you
to identify growth brands, key drug classes and leading companies
through to 2011, pin-pointing market trends that will influence future
sales of treatments within the CNS market.

Evaluate changes in the competitive positions of the leading companies in
the CNS market and ensure your R&D pipeline is aligned with future
market opportunity to maximize commercial success.

Key findings of the report…
• Sales of the leading nine companies in the CNS market were
$51,884m in 2005, 0.8% down on year previous sales reported at
$52,299m. The performance of the leading nine companies
underperformed that of the total market which recorded a growth rate
of 5.5% for 2005.
• Alzheimer’s disease is forecast to be the primary growth driver in
the CNS market over the forecast period, with a CAGR estimated at
10.3% for 2005-11. This growth is attributed to the arrival of new
products and the implementation of successful strategies by major
pharmaceutical companies to protect existing revenue streams.
• Of the most promising compounds identified in this report, five are
replacement compounds for blockbusters that have or are forecast to
lose patent protection over the forecast period to 2011. Such products
include J&J’s paliperidone, Lilly’s Symbyax, Pfizer’s Lyrica, and
Wyeth’s DVS-233.
• Epilepsy is forecast to become a fiercely competitive indication
over the forecast period with heavy genericization setting in.
Major companies are looking at different strategies in addition to new
indications to protect sales of their products from generics.

Key questions answered in this report
• What will be the major growth indications in the CNS market over
the period 2006-11?
• Which companies were the winners and losers in the CNS market in
2005?
• How have recent launches from Pfizer, AstraZeneca, Forest and
Bristol-Myers Squibb performed?
• How have the recent patent expirations on key products affected
the dynamics of the CNS market?
• How significant is the threat of generic competition to the overall
performance of the migraine, schizophrenia and epilepsy markets?
• Which pipeline products feature highest growth potential and why?
• What will the competitive landscapes of the major sub-indications of
depression, schizophrenia, Alzheimer’s disease (AD), Parkinson’s
disease (PD), and migraine look like in 2011?

Top five reasons to order your copy today
• Access the latest in research with the report’s coverage of the 6
largest indications in the CNS market, the 7 largest geographic
pharmaceutical markets and the 9 largest companies active in the
CNS market today.
• Discover which indications have the greatest potential to provide
franchise growth and how major players are attempting to utilize these
opportunities.
• Evaluate how the market share of leading companies, such as
Johnson & Johnson, Pfizer, GlaxoSmithKline and Lilly, will change
over the next 6 years and assess your company’s competitive position
within the market.
• Understand how recent events are affecting the performance of
major products, and how their marketers are confronting competitive
changes in the CNS marketplace.
• Gain access to the CNS pipelines of the 9 leading players to
understand which companies will have a presence in key indications
over the next 6 years.

Table of Contents

Executive Summary

Patient potential

Global market analysis

Analysis of potential future CNS blockbusters

Leading players in the CNS market

Chapter 1 Patient potential

Summary

Introduction

Alzheimer’s disease

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of Alzheimer’s disease

Depression

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of depression/anxiety

Epilepsy

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of epilepsy

Migraine

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of migraine

Parkinson’s disease

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of Parkinson’s disease

Schizophrenia

Background

Diagnosis and treatment

Prevalence

Forecast prevalence of schizophrenia

Chapter 2 Global market analysis

Summary

Introduction

Alzheimer’s disease

Introduction

Analysis of the leading Alzheimer’s disease treatments

Market analysis by drug class

Cholinesterase inhibitors

NMDA antagonists

Depression

Introduction

Analysis of the leading anti-depressant treatments

Market analysis by drug class

Selective serotonin reuptake inhibitors

Serotonin norepinephrine reuptake inhibitors

Others

Epilepsy

Introduction

Analysis of the leading epilepsy treatments

Market analysis by drug class

Traditional anti-convulsants

Second generation anti-convulsants

Parkinson’s disease

Introduction

Analysis of the leading Parkinson’s disease treatments

Market analysis

COMT inhibitors

Dopaminergics

Dopamine agonists

Migraine

Introduction

Analysis of the leading migraine treatments

Market analysis by drug class

Triptans

Schizophrenia

Introduction

Analysis of the leading anti-psychotic treatments

Market analysis by drug class

Typical anti-psychotics

Atypical anti-psychotics

CNS market forecasts

Chapter 3 Analysis of potential future CNS blockbusters

Summary

Introduction

Drug profiles

Phase II pipeline drugs

E 2007

Phase III pipeline drugs

Xenox (xaliproden)

Lacosamide

Asenapine

Saredutant

Alzhemed (tramipostate)

Drugs in registration

DVS-233 (desvenlafaxine)

Paliperidone

Inovelon (rufinamide)

Recently marketed drugs

Lyrica (pregabalin)

Symbyax (olanzapine/fluoxetine)

Agilect/Azilect (rasagiline)

Chapter 4 Leading players in the CNS market

Summary

Introduction

Global market shares

Johnson & Johnson

Marketed products

R&D compounds

CNS portfolio sales forecasts

Pfizer

Marketed products

R&D compounds

CNS portfolio sales forecasts

GSK

Marketed products

R&D compounds

CNS portfolio sales forecasts

Lilly

Marketed products

R&D compounds

CNS portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

CNS portfolio sales forecasts

AstraZeneca

Marketed products

R&D compounds

CNS portfolio sales forecasts

Wyeth

Marketed products

R&D compounds

CNS portfolio sales forecasts

Novartis

Marketed products

R&D compounds

CNS portfolio sales forecasts

Forest Labs

Marketed products

R&D compounds

CNS portfolio sales forecasts

Chapter 5 Appendix

Glossary

Index

List of Figures

Figure 2.1: Competitive dynamics of drug classes in the Alzheimer’s disease market, 2005

Figure 2.2: Competitive dynamics of leading brands in the Alzheimer’s disease market, 2005

Figure 2.3: Competitive dynamics of drug classes in the depression market, 2005

Figure 2.4: Competitive dynamics of leading brands in the depression market, 2005

Figure 2.5: Competitive dynamics of drug classes in the epilepsy market, 2005

Figure 2.6: Competitive dynamics of leading brands in the epilepsy market, 2004–05

Figure 2.7: Competitive dynamics of leading brands in the Parkinson’s disease market, 2005

Figure 2.8: Competitive dynamics of leading brands in the migraine market, 2005

Figure 2.9: Competitive dynamics of drug classes in the schizophrenia market, 2004–05

Figure 2.10: Competitive dynamics of leading brands in the schizophrenia market, 2004–05

Figure 3.11: Leading drugs in development, 2005

Figure 4.12: Key players in the global CNS market, 2001 and 2005

List of Tables

Table 1.1: Prevalence of Alzheimer’s disease in the seven major markets, 2005

Table 1.2: Forecast prevalence of Alzheimer’s disease in the seven major markets, 2006-11

Table 1.3: Prevalence of MDD/anxiety in the seven major markets, 2005

Table 1.4: Forecast prevalence of depression/anxiety in the seven major markets, 2006-11

Table 1.5: Prevalence of epilepsy in the seven major markets, 2005

Table 1.6: Forecast prevalence of epilepsy in the seven major markets, 2006-11

Table 1.7: Prevalence of migraine in the seven major markets, 2005

Table 1.8: Forecast prevalence of migraine in the 7 major markets, 2006-11

Table 1.9: Prevalence of Parkinson’s disease in the seven major markets, 2005

Table 1.10: Forecast prevalence of Parkinson’s disease in the seven major markets, 2006-11

Table 1.11: Prevalence of schizophrenia in the seven major markets, 2005

Table 1.12: Forecast prevalence of schizophrenia in the seven major markets, 2006-11

Table 2.13: Breakdown of the global Alzheimer’s disease market by drug class, 2001-05

Table 2.14: Breakdown of the global Alzheimer’s disease market by leading brands, 2004-05

Table 2.15: Breakdown of the global depression market by drug class, 2001-05

Table 2.16: Breakdown of the global depression market by leading brands, 2004-05

Table 2.17: Breakdown of the global epilepsy market by drug class, 2001-05

Table 2.18: Breakdown of the global epilepsy market by leading brands, 2004-05

Table 2.19: The global Parkinson’s disease market, 2004-05

Table 2.20: Breakdown of the global Parkinson’s disease market by leading brands, 2004-05

Table 2.21: Breakdown of the global migraine market by drug class, 2001-05

Table 2.22: Breakdown of the global migraine market by leading brands, 2004-05

Table 2.23: Breakdown of the global anti-psychotics market by drug class, 2001-05

Table 2.24: Breakdown of the global anti-psychotics market by leading brands, 2004–05

Table 2.25: Forecast global sales for major CNS indications, 2005-11

Table 4.26: Key players in the global CNS market, 2005

Table 4.27: J&J’s marketed CNS portfolio, 2005

Table 4.28: J&J’s CNS R&D pipeline, 2006

Table 4.29: Forecast sales for J&J’s CNS portfolio, 2005–11

Table 4.30: Pfizer’s marketed CNS portfolio, 2005

Table 4.31: Pfizer’s CNS R&D pipeline, 2006

Table 4.32: Forecast sales for Pfizer’s CNS portfolio, 2005–11

Table 4.33: GSK’s marketed CNS portfolio, 2005

Table 4.34: GSK’s CNS R&D pipeline, 2006

Table 4.35: Forecast sales for GSK’s CNS portfolio, 2005–11

Table 4.36: Lilly’s marketed CNS portfolio, 2005

Table 4.37: Lilly’s CNS R&D pipeline, 2006

Table 4.38: Forecast sales for Lilly’s CNS portfolio, 2005–11

Table 4.39: Sanofi-Aventis’ marketed CNS portfolio, 2005

Table 4.40: Sanofi-Aventis’ CNS R&D pipeline, 2006

Table 4.41: Forecast sales for Sanofi-Aventis’ CNS portfolio, 2005–11

Table 4.42: AstraZeneca’s marketed CNS portfolio, 2005

Table 4.43: AstraZeneca’s CNS R&D pipeline, 2006

Table 4.44: Forecast sales for AstraZeneca’s CNS portfolio, 2005–11

Table 4.45: Wyeth’s marketed CNS portfolio, 2005

Table 4.46: Wyeth’s CNS R&D pipeline, 2006

Table 4.47: Forecast sales for Wyeth’s CNS portfolio, 2005–11

Table 4.48: Novartis’ marketed CNS portfolio, 2005

Table 4.49: Novartis’ CNS R&D pipeline, 2006

Table 4.50: Forecast sales for Novartis’ CNS portfolio, 2005–11

Table 4.51: Forest’s marketed CNS portfolio, 2005

Table 4.52: Forest’s CNS R&D pipeline, 2006

Table 4.53: Forecast sales for Forest’s CNS portfolio, 2005–11